Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 168 followers
Latest posts
Last updated 2 days ago
Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
2 days ago
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients
4 days ago
Basel, 22 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer
6 days ago
Basel, 20 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
9 days ago
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer
9 days ago
Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche opens access to pathology imaging tools to improve patient care
11 days ago
Basel, 15 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases
17 days ago
Basel, 09 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers
19 days ago
Basel, 07 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer
30 days ago
Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
about 1 month ago
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
about 2 months ago
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...
US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
about 2 months ago
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...